MANKIND: Q2 revenue rose 17.3% as EBITDA margin expanded 210 bps to 27.1%

What happened

Mankind's second-quarter revenue rose 17.3% from a year earlier. EBITDA margin, which means profit before interest, taxes, depreciation and amortisation as a share of sales, expanded 210 basis points to 27.1%, and profit after tax rose 37.7%.

Confirmed

Global impact / market context

Faster revenue growth plus a wider EBITDA margin means Mankind kept a larger share of each sale as operating profit, helping profit after tax rise faster than sales. Strong domestic ex-Consumer Healthcare and export growth offset softer Consumer Healthcare.

Analyst inference

The results show broad-based demand in most Mankind businesses, but muted Consumer Healthcare limits the picture. Investors may weigh whether margin gains persist and whether Consumer Healthcare recovers, since slower growth there could hold back overall revenue momentum.

Analyst inference

What to watch

1. Watch whether Consumer Healthcare growth remains muted in coming quarters, since it was the weakest part of the reported quarter and could limit overall revenue growth. Confirmed
2. Monitor whether the 27.1% EBITDA margin holds as sales mix shifts, because faster growth in lower-margin segments could reduce profit per sale. Proposed
3. Track domestic ex-Consumer Healthcare and export momentum, as these drove strong growth and may determine whether double-digit revenue gains continue. Analyst inference

Evidence

• Original source link unavailable